PTC Therapeutics, Inc. Financials

Market Capitalization $3.89 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	7.54
Forward PE	-13.33
Price to Sales TTM	$2.19
Price to Book MRQ	$-20.63
Enterprise to Revenue	2.44
Enterprise to EBITDA	4.82

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	33.56%
Operating Margin	82.43%
Return on Assets TTM	24.42%
Return on Equity TTM	33.08%

Income Statement

Revenue TTM	$1,772,758,016
Revenue per Share TTM	$22.95
Quarterly Revenue Growth	459.70%
Gross Profit TTM	$1,189,913,984
EBITDA	$35,360,000
Net Income to Common TTM	$594,843,008
Diluted EPS TTM	$6.51
Quarterly Earnings Growth YoY	459.73%

Balance Sheet

Total Cash MRQ	$2,037,817,984
Total Cash per Share MRQ	$25.71
Total Debt MRQ	$
Total Debt to Equity MRQ	-13.39
Current Ratio MRQ	3.89
Book Value per Share MRQ	$-2.35

Cash Flow

Operating Cash Flow TTM	$691,654,016
Levered Free Cash Flow TTM	$525,996,992

PTCT Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	77,704,188
Float Shares	64,407,424
Avg 10 Volume	1,193,505
Avg 30 Volume	None
Shares Short	5,072,028
Short Ratio	5.01
Short % of Shares	7.36%
% Held by Insiders	2.40%
% Held by Institutions	101.06%

Stock Price Summary

Beta	0.51
Fifty Two Week Low	$29.02
Fifty Two Week High	$58.38
Fifty Two Week Change	36.97%
Day 50 MA	$48.27
Day 200 MA	$46.04

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date